Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Kathy Davy, VP of Oncology at Thermo Fisher Scientific Shares Insights on the Real-World Data from Patients with NSCLC at ASCO 2022
VIEWPOINTS

PharmaShots Interview: Kathy Davy, VP of Oncology at Thermo Fisher Scientific Shares Insights on the Real-World Data from Patients with NSCLC at ASCO 2022

Shots: Kathy spoke about the major outcomes from the real-world evidence data presented at the ASCO 2022 Kathy also emphasized on how next-generation sequencing can improve genomic testing The interview gives a view of Thermo Fisher’s vision to bring targeted sequencing that provides faster results for clinicians Smriti: Tell us in detail about the key…
July 20, 2022

Read more

PharmaShots Interview Mahesh Karande, CEO of Omega Therapeutics Shares Insights from the Preclinical Data Presented at the AACR 2022
VIEWPOINTS

PharmaShots Interview: Mahesh Karande, CEO of Omega Therapeutics Shares Insights from the Preclinical Data Presented at the AACR 2022

Shots: Mahesh talked about the data presented on its lead candidate in hepatocellular carcinoma at the AACR 2022 Mahesh also spoke about Omega’s drug-development platform that identifies and targets specific and unique DNA sequences of regulatory elements  The interview gives a profound grip on Omega’s development strategies to use mRNA therapeutics as a new class…
July 19, 2022

Read more

Exclusive_Kyle Forcier_2022
EXCLUSIVE

Kyle Forcier, Senior Director of Life Sciences Product Marketing at Model N Shares Insights on How Model N Helps Life Sciences Companies Navigate Greater Compliance Pressure

Shots: Kyle Forcier gave a detailed view of the Spring 2022 product release by Model N and how it will be a practical solution for the Pharmaceutical and MedTech companies Kyle also spoke about Model N’s Revenue Cloud, which can empower MedTech Sales with better revenue recognition The interview gives a glimpse of Model N’s…
July 11, 2022

Read more

PharmaShots Interview In Conversation with ViiV Healthcare's Sr. VP, Kimberly Smith, Where she Shares Insights on the US FDA Approval for Label Update of its Lead Candidate in HIV
VIEWPOINTS

PharmaShots Interview: In Conversation with ViiV Healthcare’s Sr. VP, Kimberly Smith, Where she Shares Insights on the US FDA Approval for Label Update of its Lead Candidate in HIV

Shots: Kimberly talked about the approval for label update of ViiV’s lead candidate in HIV, and how an optional oral lead-in will be efficient for people receiving it Kimberly also spoke about ViiV’s collaboration with Janssen for the commercialization of the product  The interview gives an understanding of the different treatment options for HIV and…
June 29, 2022

Read more

PharmaShots Interview In Conversation with Four Prominent Leaders from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference
VIEWPOINTS

PharmaShots Interview: In Conversation with Four Prominent Leaders* from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference

Shots: The interview provided an understanding of the data from its Alzheimer’s disease pipeline at the AD/PD Conference The spokespeople also talked about the clinical trial data and key mechanisms of Eisai’s anti-amyloid compound in AD  The discussion showed gave a gist of four key symposium presentations that showed how its lead candidate has the…
June 27, 2022

Read more

PharmaShots Interview In Conversation with SOTIO’s CMO, Richard Sachse, Where he Shares Insights on New Interim Data presented in an Oral Presentation at AACR 2022 Annual Meeting
VIEWPOINTS

PharmaShots Interview: In Conversation with SOTIO’s CMO, Richard Sachse, Where he Shares Insights on New Interim Data presented in an Oral Presentation at AACR 2022 Annual Meeting

Shots: Richard spoke about the results from the Phase 1 AURELIO-03 study of IL-15 superagonist Richard also emphasized the clinical benefits of the IL-15 superagonist when combined with pembrolizumab The interview gives a profound understanding of the existing & developing cancer therapies as treatment options for solid tumors Smriti: Explain the details (MOA, ROA, formulations, etc.)…
June 22, 2022

Read more

PharmaShots Interview In Conversation with Cecelia’s CMO, Arnold Saperstein, Where he Shares Insights on Improving Outcomes for Children and Adolescents Living With Type 1 Diabetes (T1D)
VIEWPOINTS

PharmaShots Interview: In Conversation with Cecelia’s CMO, Arnold Saperstein, Where he Shares Insights on Improving Outcomes for Children and Adolescents Living With Type 1 Diabetes (T1D)

Shots: Arnold spoke about Cecelia Health’s collaboration with the UBMD Paediatrics for a clinical study to improve health outcomes for children and adolescents living with T1D Arnold also gave his views on how telehealth options can support the unmet needs of patients with T1D The interview provides a gist of the challenges of living with…
June 20, 2022

Read more

PharmaShots Interview In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can Trigger an Immune Priming Effect
VIEWPOINTS

PharmaShots Interview: In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can Trigger an Immune Priming Effect

Shots: Leonard spoke about the newly developed radiotherapy-activated nanoparticle and other cancer therapies developing in Nanobiotix’s pipeline James shared his views on the data presented at the 2022 Annual Meeting of the American Association of Cancer Research The interview provides a core understanding of Nanobiotix’s outlook to expand the utility of nanoparticles in cancer treatment…
June 15, 2022

Read more

PharmaShots Interview In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs
VIEWPOINTS

PharmaShots Interview: In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs

Shots: Ian spoke about the study design of the clinical trials of its lead iNKT agonists He also emphasized the advancement of novel immunotherapies through new collaborations  The interview provides a gist of Portage's development plan for its pipeline and various options to improve cancer treatment Smriti: Explain the details (MOA, ROA, formulations, etc.) of PORT-2 & PORT-3?…
June 8, 2022

Read more

PharmaShots Interview In Conversation with Cidara’s CEO, Dr.Jeff Stein, Where he Shares Insights on the IND acceptance by the FDA to Treat Influenza
VIEWPOINTS

PharmaShots Interview: In Conversation with Cidara’s CEO, Dr.Jeff Stein, Where he Shares Insights on the IND acceptance by the FDA to Treat Influenza

Shots: Jeff spoke about IND acceptance by the US FDA for its lead flu drug-Fc conjugate immunotherapy for the prevention and treatment of Influenza He also discussed Cidara’s collaboration with Janssen Pharmaceuticals to develop and commercialize Cidara’s DFCs The interview also emphasizes Cidara’s Cloudbreak platform to develop immunotherapeutic antivirals and treatment options for influenza Smriti:…
June 6, 2022

Read more

Load more